Treatment with Aspirin and Dipyridamole is More Effective than Aspirin in Reducing Low Shear Blood Viscosity

References

• Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lwenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1–13
   PubMed Web of Science ®Google Scholar
• Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomized, controlled trial. Lancet 2006; 367: 1665–1673
   PubMed Web of Science ®Google Scholar
• Aarts PA, Heethaar RM, Sixma JJ. Red blood cell deformability influences platelet-vessel wall interaction in flowing blood. Blood 1984; 64: 1228–1233
   PubMed Web of Science ®Google Scholar
• Glaser R. Mechanisms of electromechanical coupling in membranes demonstrated by transmembrane potential-dependent shape transformation of human erythrocytes. Bioelectrochem Bioenerg 1993; 30: 103–109
   Web of Science ®Google Scholar
• Saniabadi AR, Fisher TC, Lau CS, Bridges A, Taylor J, Belch J, Forbes CD. Dipyridamole increases human red blood cell deformability. Eur J Clin Pharmacol 1992; 42: 651–654
   Google Scholar
• Bergfeld GR, Forrester T. Release of ATP from human erythrocytes in response to a brief period of hypoxia and hypercapnia. Cardiovasc Res 1992; 26: 40–47
   PubMed Web of Science ®Google Scholar
• Gresele P, Amout J, Teckmyn H, Vermylen J. Mechanism of antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity. Thromb Haemost 1986; 55: 12–17
   PubMed Web of Science ®Google Scholar
• Klabunde RE. Effects of dipyridamole on postischemic vasodilatation and extracellular adenosine. Am J Physiol 1983; 244: 273–280
   Google Scholar
• Ferrandon P, Barcelo B, Armstrong JM. A comparison of the effects of ranolazine, lidoflazine and dipyridamole on the uptake and catabolism of adenosine in human red blood cells. Fundam Clin Pharmacol 1991; 5: 456–459
   Google Scholar
• Chakrabarti S, Viseva O, Iyu D, Varghese S, Freedman JE. The effect of dipyridamole on vascular cell-derived reactive oxygen species. J Pharmacol Exp Ther 2005; 315: 494–500
   Google Scholar
• Costello PB, Green FA. Aspirin survival in human blood modulated by the concentration of erythrocytes. Arthritis Rheum 1982; 25: 550–555
   PubMed Web of Science ®Google Scholar
• Nappo F, De Rosa N, Marfella R, De Lucia D, Ingrosso D, Perna AF, Farzati B, Giugliano D. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 1999; 281: 2113–2118
   PubMed Web of Science ®Google Scholar
• Wang S, Boss AH, Kensey KR, Rosenson RS. Variations of whole-blood viscosity using Rheolog™—a new scanning capillary viscometer. Clin Chim Acta 2003; 332: 79–82
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Wolff D. Comparison of two whole-blood viscometers: implications for cardiovascular and thrombosis research. Thromb Haemost 2004; 92: 225–226
   Google Scholar
• Lee AJ, Mowbray PI, Lowe GD, Rumley A, Fowkes FG, Allan PL. Blood viscosity and elevated carotid intima-media thickness in men and women: the Edinburgh Artery Study. Circulation 1998; 97: 1497–1473
   Google Scholar
• Lowe GDO, Lee AJ, Rumley A, Price JF, Fowkes FG. Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Br J Haematol 1997; 96: 168–173
   PubMed Web of Science ®Google Scholar
• Coull BM, Beamer N, de Garmo P, Sexton G, Nordt F, Knox R, Seaman GV. Chronic blood hyperviscosity in subjects with acute stroke, transient ischemic attack, and risk factors for stroke. Stroke 1991; 22: 162–168
   PubMed Web of Science ®Google Scholar
• Resch KL, Ernst E, Matrai A, Paulsen HF. Fibrinogen and viscosity as risk factors for subsequent cardiovascular events in stroke survivors. Ann Intern Med 1992; 117: 371–375
   PubMed Web of Science ®Google Scholar
• Bozzo J, Escolar G, Hernandez MR, Galán AM, Ordinas A. Prohemorrhagic potential of dipyrone, ibuprofen, ketorolac, and aspirin: mechanisms associated with blood flow and erythrocyte deformability. J Cardiovasc Pharmacol 2001; 38: 183–190
   Google Scholar
• Strano A, Davi G, Avellone G, Novo S, Pinto A. Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs. Angiology 1984; 35: 439–446
   Google Scholar
• Störmer B, Kleinschmidt K, Loose D, Kremer K. Rheological changes in the blood of patients with chronic arterial occlusive disease after the administration of vasoactive drugs. Curr Med Res Opin 1977; 4: 588–595
   PubMed Web of Science ®Google Scholar
• Dawson DL, Zheng Q, Worthy SA, Charles B, Bradley DVJr. Failure of pentoxifylline or cilostazol to improve blood and plasma viscosity, fibrinogen, and erythrocyte deformability in claudication. Angiology 2002; 53: 509–520
   Google Scholar
• Rosenson RS, Wolff D, Green D, Boss AH, Kensey KR. Aspirin does not alter native blood viscosity. J Thromb Haemost 2004; 2: 340–341
   Google Scholar
• Akhtar M, Ordovas K, Martin A, Higgins CB, Michaels AD. Effect of chronic sustained-release dipyridamole on myocardial blood flow and left ventricular function in patients with ischemic cardiomyopathy. Congest Heart Fail 2007; 13: 130–135
   Google Scholar
• Rosenson RS. Viscosity and ischemic heart disease. J Vasc Med Biol 1993; 4: 206–212
   Google Scholar